Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Risdiplam Formulations in Healthy Subjects
NCT04718181Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risdiplam in spinal muscular atrophy (SMA) (3 arms), sponsored by Roche. Primary endpoint: Plasma Concentration of Risdiplam. Started Feb 2021; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT04718181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718181.